Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;12(4):735-757.
doi: 10.1007/s13346-020-00891-5. Epub 2021 Jan 25.

Intranasal drug delivery: opportunities and toxicologic challenges during drug development

Affiliations
Free PMC article
Review

Intranasal drug delivery: opportunities and toxicologic challenges during drug development

Lea-Adriana Keller et al. Drug Deliv Transl Res. 2022 Apr.
Free PMC article

Abstract

Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development.

Keywords: Intranasal drug delivery; Nasal toxicity; Nose-to-brain-delivery; Olfactory pathways.

PubMed Disclaimer

References

    1. Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8 - PubMed
    1. Adv Drug Deliv Rev. 2018 Aug;133:57-65 - PubMed
    1. J Allergy Clin Immunol. 2000 Jan;105(1 Pt 1):39-44 - PubMed
    1. Biochim Biophys Acta. 2009 Apr;1788(4):892-910 - PubMed
    1. Ther Deliv. 2019 Apr;10(4):207-210 - PubMed

Publication types

Substances